RXi Pharmaceuticals Corp | 2013 | FY | 3


11. Development Stage Supplemental Equity Disclosure

Summarized below are the Company’s equity (common stock and common stock options) transactions since the Company’s inception through December 31, 2013.

 

Type of Security

  

Date of Issuance

   Shares of
Common
Stock
     Dollar
Amount of
Consideration
($)
     Price per
Share or
Exercise
Price per
Share
($)
    

Counter

Party to

Transaction

  

Nature of

Non-Cash

Consideration

  

Basis of

Assigning Cost

Common Stock

   September 8, 2011      100         —           0.01       Galena    NA    Cash

Common Stock

   April 27, 2012      3,347,996         NA         0.27       Galena    NA    Independent Third Party Valuation

Common Stock

   April 27, 2012      1,394,997         NA         4.43       Advirna    Intellectual Properties    Market Value

Common Stock

   Various - 2012      546,014         NA         0.41      

Conversion of

Series A

Preferred Stock

   NA    Cost Basis

Common Stock

   March 12, 2013      3,765,230         15,651         4.35       PIPE    NA    Net Cash

Common Stock

   March 12, 2013      1,666,666         NA         4.35       Opko    Intellectual Properties    Market Value

Common Stock

   Various - 2013      1,056,684         NA         0.41      

Conversion of

Series A

Preferred Stock

   NA    Cost Basis

Common Stock

   September 11, 2013      2,000         5         2.55      

Exercise of

Stock Options

   NA    Cash

Common Stock

   December 31, 2013      11,265         28         2.61       ESPP    NA    Cash

us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock